HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer

被引：0
|
作者：
Hamilton, Erika P.
Martin, Miguel
O'Sullivan, Ciara Catherine
Curigliano, Giuseppe
Sohn, Joohyuk
Tsurutani, Junji
Tryfonidis, Konstantinos
Santarpia, Libero
Yang, Shan
Dieras, Veronique
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashiville, TN USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Mayo Clin, Rochester, MN USA
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Yonsei Canc Ctr, Seoul, South Korea
[6] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[7] Merck & Co Inc, Rahway, NJ 07065 USA
[8] Seagen Inc, Bothell, WA USA
[9] Ctr Eugene Marquis, Rennes, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1115
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Mueller, V
    Hamilton, E.
    Tsurutani, J.
    Curigliano, G.
    Martin, M.
    O'Sullivan, C.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 173 - 173
  • [2] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Hamilton, Erika
    Tsurutani, Junji
    Sohn, Joohyuk
    Curigliano, Giuseppe
    O'Sullivan, Ciara C.
    Martin, Miguel
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    CANCER RESEARCH, 2023, 83 (08)
  • [3] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Hamilton, Erika
    Tsurutani, Junji
    Curigliano, Giuseppe
    Martin, Miguel
    O'Sullivan, Ciara C.
    Sohn, Joo Hyuk
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress).
    Hamilton, Erika P.
    Maria O'Sullivan, Ciara Catherine
    Martin, Miguel
    Sohn, Joohyuk
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Kiver, Verena
    Hamilton, Erika
    Tsurutani, Junji
    Curigliano, Giuseppe
    Martin, Miguel
    O'sullivan, Ciara
    Sohn, Joo Hyuk
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 39 - 39
  • [6] Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+Metastatic Breast Cancer (HER2CLIMB-05, Trial in Progress)
    Hamilton, Erika
    Tsurutani, Junji
    Curigliano, Giuseppe
    Martin, Miguel
    O'Sullivan, Ciara
    Sohn, Joo Hyuk
    Tryfonidis, Konstantinos
    Santarpia, Libero
    Yang, Shan
    Dieras, Veronique
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Dieras, V. C.
    Martin Jimenez, M.
    O'Sullivan, C. C. M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2022, 33 : S222 - S222
  • [8] Phase 3 study of maintenance treatment of tucatinib or placebo in combination with trastuzumab and pertuzumab in HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Muller, V
    Hamilton, E.
    O 'Sullivan, C.
    Martin, M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [9] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)
    Park-Simon, T. -W
    Okines, A.
    Paplomata, E.
    Wahl, T.
    Wright, G.
    Sutherland, S.
    Jakobsen, E.
    Valdes-Albini, F.
    Chan, A.
    Clark, A. S.
    Conlin, A.
    Lustberg, M.
    Specht, J.
    Pluard, T.
    Zhu, X.
    Krop, I
    Gelmon, K.
    Slamon, D.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 243 - 244
  • [10] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).
    Okines, Alicia Frances Clare
    Paplomata, Elisavet
    Wahl, Tanya A.
    Wright, Gail Lynn Shaw
    Sutherland, Stephanie
    Jakobsen, Erik
    Valdes, Frances
    Chan, Arlene
    Clark, Amy Sanders
    Conlin, Alison Katherine
    Lustberg, Maryam B.
    Specht, Jennifer M.
    Pluard, Timothy J.
    Zhu, Xiaofu
    Krop, Ian E.
    Gelmon, Karen A.
    Slamon, Dennis J.
    Ramos, Jorge
    An, Grace
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345